The postdoctoral researcher will contribute to this project using
a combination of evolutionary and comparative genomics, as well as a
diverse set of bioinformatic approaches for data analysis and integration
(e.g., transcriptomics, genomics, phenotypic data). This position offers
a unique opportunity to integrate diverse state-of-the-art genomic and
phenotypic datasets across different model organisms to understand the
role of genes, molecular pathways in the origin of complex diseases.

CINV provides a highly collaborative and multidisciplinary environment
using a variety of computational and experimental approaches,
including genetically tractable animal models as well as expertise in
genetics, behavior, glia-neuron communication, metabolism, biophysics,
genomics, bioinformatics, host-microbe communication, and biomolecular
modelling. The new postdoc will be part of one of our labs which focuses
more generally on the intersection between molecular evolution and
disease biology.

Required qualifications are a PhD in evolutionary biology, computational
biology, bioinformatics, or closely related fields. Candidates must have
excellent verbal and written communication skills (working language
is English), as well as an established record of productivity (e.g.,
at least one previous peer-reviewed publication). Candidates with a
past record of publications in bioinfomatics, computational biology,
population genetics or evolutionary genomics are strongly preferred. Ideal
candidates should have experience in analyzing genomic and phenomic
data, performing comparative evolution or population genomic analyses,
as well as in collaborating with experimentalists.

Interested candidates should first contact Evandro Ferrada at
. Please include the following: (1) a cover
letter addressing your interest in the position and how your expertise
meets the position requirements, (2) a CV, (3) contact information of
at least 2 references. A short online interview will follow to discuss
specific proposals. Candidate materials will be reviewed as soon as
possible until the position is filled.

For further information, please visit:
https://cinv.uv.cl/cinv-postdoctoral-fellowship-program-2026/

Dr. Evandro Ferrada
Associate Profesor

Centro Interdisciplinario de Neurociencia (CINV)

Facultad de Ciencias, Universidad de Valpara�so.

Pasaje Harrington 287, Playa Ancha, Valpara�so, Chile.

Tel. +56 (32) 250 8453

www.cinv.cl

Research with the help of bioinformatics with a trans-disciplinary approach is yielding good results.

http://www.thehindu.com/features/education/research/research-with-help-of-bioinformatics-helpful/article2295629.ece

Modern sequencing technologies have turned biology into a data-heavy science. The human genome has about three billion DNA base pairs, and sequencing can produce massive datasets quickly. Bioinformatics helps organize and interpret this information, allowing scientists to compare genomes, find genes, spot genetic differences, study gene expression, and understand diseases at the molecular level. Now, AI is changing how these datasets are analyzed. Machine learning and deep learning can find complex patterns in biological data and make predictions using large datasets. Rather than following only set rules, AI systems can learn from data and help researchers solve tough biological problems.

A key example of AI in bioinformatics is predicting protein structures. Proteins are vital for many functions in living things, and their three-dimensional shapes are closely tied to what they do. For a long time, figuring out these structures in the lab was slow and difficult. AI-based tools like AlphaFold have shown that deep learning can predict protein structures with impressive accuracy. These advances help speed up biological research and give scientists useful predictions to support their experiments. This shift means bioinformatics is moving from just analyzing biological data to predicting how biology works and designing new solutions.

AI is also expected to greatly influence drug discovery. Traditionally, developing a new drug is a long and costly process that involves finding biological targets, searching for possible drug molecules, testing how well they work, studying their properties, and running many experiments. AI can help researchers analyze large chemical and biological datasets, predict how molecules might interact with targets, find promising compounds, and estimate properties of drug candidates. Generative AI can even help design new molecules to test in the lab. This does not mean lab experiments will go away, but AI can help researchers focus on the best options and possibly speed up some parts of drug development.

Personalized medicine is another area where AI-driven bioinformatics could make a big difference. Each person has a unique mix of genetic, molecular, environmental, and lifestyle factors, so people with the same disease might respond differently to the same treatment. Bioinformatics lets researchers study individual biological data, and AI can combine many types of information, like genetic data, gene expression, protein levels, medical images, clinical records, and drug responses. In the future, this could help doctors look beyond just the disease and focus on the specific biology of each patient. This would support more personalized ways to diagnose, assess risk, and choose treatments.

As AI becomes more common, the job of bioinformaticians will likely change. Instead of spending most of their time on repetitive computer tasks, they may focus more on creating research questions, understanding AI results, checking predictions, and linking computer findings to lab experiments. Future professionals will need to know about molecular biology, genetics, statistics, programming, machine learning, data science, databases, and computational biology. But technical skills alone will not be enough. Being able to ask good scientific questions and carefully judge computer results will be even more important, since AI can make predictions, but scientists must decide if those predictions make sense and can be proven in the lab.

Even with its great potential, using AI in bioinformatics comes with big challenges. AI systems rely on the quality and variety of the data they are trained on. Biological and clinical datasets can have missing information, technical errors, inconsistent measurements, and may not represent all groups equally. A model that works well on one dataset might not work as well on another group or in a different setting. That is why data quality, proper validation, transparency, reproducibility, and careful model development are crucial for the future of AI in bioinformatics. Researchers also need to think about genetic privacy, data ownership, security, and using personal biological information responsibly. These concerns are especially important when AI predictions are used in healthcare.

The lab of the future may look very different from today’s. Researchers might use AI to review scientific papers, find research questions, analyze large datasets, come up with ideas, and predict which experiments will be most helpful. Automated lab systems could then run these experiments, create new data, and send the results back to computer models. This would create a cycle of making guesses, predicting, experimenting, collecting data, and learning. This approach could speed up scientific discovery by helping researchers explore questions more efficiently. Bioinformatics could become a key link between computer predictions and real lab experiments.

In the end, the future of bioinformatics with AI will not be about replacing people with machines. It will be about humans and AI working together. Computers can handle huge amounts of biological data and spot patterns that a single person could not. But humans bring scientific understanding, creativity, critical thinking, ethical judgment, and the ability to see the bigger picture. AI might find a pattern in millions of genomes, but scientists need to figure out why it matters. An AI model could suggest a new drug, but researchers must check if it is safe and works well. A computer might find a genetic change, but doctors have to decide what it means for a real patient.

The future of bioinformatics is closely tied to the future of AI. As biological data grows and AI models get better, bioinformatics may shift from mainly analyzing data to predicting biological processes, designing new molecules, speeding up experiments, and supporting personalized healthcare. For students and researchers, this is an exciting chance to work where biology and technology meet. The most successful people will not just be those who use the latest AI tools, but those who understand biology well enough to ask good questions and judge the answers carefully. The future will not be about AI versus humans, but about people and AI working together to understand life in ways we never could before. The next big discovery may come from this partnership between a biological question, a computer model, a lab experiment, and human curiosity.

The most common newbie questions are:

Should I try to use these free open source programs?  Why are we not trying GUI software for computational analysis? Should I use commercial bioinformatics programs/software?”

1. Let’s be open

We generally think free and cheap are useless. But this concept is not applicable when we discuss open source software. Mostly, the bioinformatics software is developed by highly competitive biological programmers who believe in open sharing of knowledge. They come under Open Bioinformatics Foundation or O|B|F which is a non-profit, volunteer run organization focused on supporting open source programming in bioinformatics. The best part about open source tools/software is that they’re free to download the source code and read exactly what the program does. If you are so inclined, you can view all of the parts of the program and see the logical flow of the pipeline. In addition, open source makes an excellent learning tool for any beginning bioinformatician. Moreover, you can modify existing open source programs to deal with cutting-edge problems or to customize your pipeline. Apart from your computational and analysis work, most of the reviewer also prefers the open source based results so that they can validate the results if validation required.

2. Code headache

As a bioinformatician you are supposed to know the basics of programming languages, and if you are not good at it, then please learn it as soon as possible because you are not a bio-analyst but biological programmers. The open source programs usually lack dedicated service and support teams (often because they were the product of an overworked doc/postdoc!) so you are responsible for troubleshooting your own errors most of the time. We commonly receive the HELP email to support and assist to setup the pipeline; you can also find this kind of request on any QA forum. I personally believe this coding horror brings the biggest downside of open-source programs; where you need some programming skills in order to implement the program in your pipeline. But, if you are not able to fix the pipeline and modify the open source code according to your requirements them you should re-think on your bioinformatician name tag!!!

3. Dive into the codes

Some of the biologist turn bioinformatician says “if you can do the same thing with commercial software then why to get migraine with weird codes”, well this statement looks to me that guys are keen to learn swimming but still don’t like to get wet. If you are still using paid software and doing your work by customer support and clicking some of the well-designed GUI button then perhaps you are not interested in learning and trying new and challenging bioinformatics works. You are missing the basic flavour of bioinformatics. Let’s dive into the coding world, I am sure your will enjoy it. I recommend your to swim freely in code’s sea, and enjoy the journey; do not merely watch it from the outside.  

4. Paid does not mean better

The bioinformatics company which are specializes in bioinformatics solutions develop well designed/packed, user friendly software by using a large number of specialised scientist, programmers and support staff. They also provide good services to accomplice your biological analysis work. This means that if you hit a ‘snag’ with your data, help is likely only a phone call away! These companies price their products competitively against the cost of a dedicated bioinformatician. You may be able to afford the program, but not the additional staff! Additionally, most of the functionality that you need in your analysis is already coded into the program. Need to plot a graph? Just click this button right here. It is that easy. But, as a bioinformatician this is not generally well encouraged approach in biological analysis work, because the software is not available to everyone and your data can’t be validated. Moreover, there is very less chances that anyone will repeat your work or love to do similar kind of research (because not all the labs in the world are rich like yours).

5. Take a caution

In biological analysis work, in which you deal GB/TB of data are having maximum chances of getting errors, so please be careful and always cross check your data before coming to any conclusion. Even an error in two line code can alter your entire analysis and display weird results. Some of the scientist blindly believes on commercial software, which is entirely wrong. Using proprietary tools does not absolve you of the need to actually read and research the type of analysis that you are doing. This is particularly true in the case of genome assembly and annotation.

At the end, I would like to tell only one think that open source solutions allows you to do more cutting edge analysis than the commercial tools. So let’s go for it.

Disclaimer:

This is my personal view. I have nothing to do with any company or open source community. The views expressed on these pages are mine alone and not those of my current/past employers. I do reserve the right to remove comments left by spammers or off-topic comments.

Genomics England will play a key role in building on the UK’s long track record as leader in medical science advances to push the boundaries by unlocking the power of DNA data. The UK will become the first ever country to introduce this technology in its mainstream health system – leading the global race for better tests, better drugs and above all better, more personalised care.

http://www.genomicsengland.co.uk/100k-genome-project/

Address of the bookmark: http://www.genengnews.com/keywordsandtools/print/3/32115/

SciGenom Research Foundation (SGRF) and Institute of Genomics and Integrative Biology (IGIB) are pleased to host the Next-Generation Sequencing and Bioinformatics for Genomics & Healthcare conference.

In the ten years since the first human reference genome was completed for US$3 billion the sequencing technologies have radically changed leading to great reduction in sequencing cost. Today a human genome can be sequenced for under US$ 5000 in less than two weeks. It is expected that by the end of 2015 the cost of sequencing a human genome will drop to below thousand dollars. The next generation sequencing technologies over the past five years have enabled a large number of genomic studies that impact human health and disease. Also, this has made possible the growth of microbial, animal and plant genomics studies. While the data production has increased at a rapid pace challenges remain in analyzing and understanding the data. The conference will cover the next generation sequencing (NGS) technologies, bioinformatics for NGS and applications of NGS in many areas including personalized medicine.

For more info : http://www.scigenomconferences.com/2013/default.php

• The market size of the Indian Bioinformatics Industry , FY’2007-FY’2013
• Market segmentation of India bioinformatics industry by application by sectors, FY’2007-FY’2013
• Market Segmentation of India bioinformatics industry by products and services,FY’2007-FY’2013
• Market Segmentation of India bioinformatics industry by applications of bioinformatics ,FY’2007-FY’2013
• India bioinformatics industry trends and developments
• Government regulations and initiatives of India bioinformatics industry
• Major bioinformatics research institutes in India
• Market Share of leading players in bioinformatics industry in India,FY’2013
• Company profiles of major players in India bioinformatics industry
• Future outlook and projections on the basis of revenue in India bioinformatics market, FY’2014-FY’2018

                                                                                                         (Source: Ken Research)

Address of the bookmark: http://www.kenresearch.com/healthcare/biotechnology/india-bioinformatics-industry-research-report/392-91.html

Candidates must have: a PhD degree in statistics, biostatistics or bioinformatics, extensive experience in analyzing high-dimensional data (microarray, SNP, CNVs) and of validation approaches. In addition, experience in penalized regression methods, data base manipulation; and strong programming skills in order to conduct Monte Carlo studies and applications (R). Candidate must have excellent communication skills (verbal, written and presentation), a strong proficiency in Linux system.

This position is available immediately and will be filled as soon as possible. Appointment could be extended beyond the first year based on additional funding.

For more information about the Department of Biostatistics and Bioinformatics, please visit our website: http://www.biostat.duke.edu.

For more info: http://biostat.duke.edu/sites/biostat.duke.edu/files/Halabi%20-%20Postdoc%20Job%20Posting%202013%20updated.pdf

Duke University is an Equal Opportunity/Affirmative Action Employer.

genomic scale studies
endogenous mechanisms of mutations, germ line and somatic
computational aspects of immunology in cancer
signalling networks
three-dimensional organization of information in the nucleus
gene silencing
metastatic cross-talk
kinase signaling
personalized medicine
detection of biomarkers in cancer
historical DNA variation

From : http://www.ous-research.no/hovig/

Group address:
Eivind Hovig, The Norwegian Radium Hospital, Montebello, 0310 Oslo,Norway
Email: ehovig@radium.uio.no